# Ocugen Agrees to Sell OCU400 Rights in Australia, New Zealand and the ASEAN Region

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54209
Published: 2026-11-11T16:20:23.000Z
Updated: 2026-11-11T16:20:23.000Z
Section: Business

> The agreement would give Australian biopharma Celairis Therapeutics exclusive commercialization rights to the gene therapy candidate in those areas.

Ocugen agreed to sell Celairis Therapeutics exclusive commercialization rights to OCU400 in Australia, New Zealand and the ASEAN region. The agreement would give the Australian biopharma rights to the gene therapy candidate across those areas.

Ocugen and Celairis announced the agreement Tuesday, Nov. 10.